Pablo Velasco Puyó

Pablo Velasco Puyó

Auto-generated profile, based on publicly available information

Pablo Velasco Puyó

25Department of Pediatric Oncology and Hematology, Hospital Vall d'Hebron, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2017 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
ELE. Llaudet‐Planas
E. Llaudet‐Planas
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
VRV. Rizzuto
V. Rizzuto
PGP. Gómez‐Ramírez
P. Gómez‐Ramírez
JSJulián Sevilla
Julián Sevilla
MMM. M. Mañú‐Pereira
M. M. Mañú‐Pereira

21 November 2024 in Blood
Verified
Journal Article
Open access
TBTeena Bhatla
Teena Bhatla
LHLaura E. Hogan
Laura E. Hogan
DTDavid Trent Teachey
David Trent Teachey
FSFrancisco Jose Bautista Sirvent
Francisco Jose Bautista Sirvent
JMJohn Moppett
John Moppett
AVAjay Vora
Ajay Vora
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg IV) plus backbone chemotherapy in children with relapsed/refractory B-cell ALL (n = 7) after ≥2 relapses, and children and young adults with T-cell ALL (children, n = 24; young adults, n = 5) or LL (n = 10) after first relapse. The primary end point was complete response (CR) in the B-cell ALL (end of cycle 2) and T-cell ALL (end of cycle 1) cohorts, after which patients could proceed off study to allogeneic hematopoietic stem cell transplant (HSCT). Seven patients with advanced B-cell ALL received daratumumab with no CRs achieved; this cohort was closed because of futility. For the childhood T-cell ALL, young adult T-cell ALL, and T-cell LL cohorts, the CR (end of cycle 1) rates were 41.7%, 60.0%, and 30.0%, respectively; overall response rates (any time point) were 83.3% (CR + CR with incomplete count recovery [CRi]), 80.0% (CR + CRi), and 50.0% (CR + partial response), respectively; minimal residual disease negativity (<0.01%) rates were 45.8%, 20.0%, and 50.0%, respectively; observed 24-month event-free survival rates were 36.1%, 20.0%, and 20.0%, respectively; observed 24-month overall survival rates were 41.3%, 25.0%, and 20.0%, respectively; and allogeneic HSCT rates were 75.0%, 60.0%, and 30.0%, respectively. No new safety concerns with daratumumab were observed. In conclusion, daratumumab was safely combined with backbone chemotherapy in children and young adults with T-cell ALL/LL and contributed to successful bridging to HSCT. This trial was registered at www.clinicaltrials.gov as NCT03384654.

22 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
OMOscar Molina
Oscar Molina
ABAlex Bataller
Alex Bataller
NTNamitha Thampi
Namitha Thampi
JRJordi Ribera
Jordi Ribera
IGIsabel Granada
Isabel Granada
PMPablo Menendez
Pablo Menendez
Hypodiploidy with less than 40 chromosomes is a rare genetic abnormality in B-cell acute lymphoblastic leukemia (B-ALL). This condition can be classified based on modal chromosome number as low-hypodiploidy (30–39 chromosomes) and near-haploidy (24–29 chromosomes), with unique cytogenetic and mutational landscapes. Hypodiploid B-ALL with <40 chromosomes has an extremely poor outcome, with 5-year overall survival rates below 50% and 20% in childhood and adult B-ALL, respectively. Accordingly, this genetic feature represents an adverse prognostic factor in B-ALL and is associated with early relapse and therapy refractoriness. Notably, half of all patients with hypodiploid B-ALL with <40 chromosomes cases ultimately exhibit chromosome doubling of the hypodiploid clone, resulting in clones with 50–78 chromosomes. Doubled clones are often the major clones at diagnosis, leading to “masked hypodiploidy”, which is clinically challenging as patients can be erroneously classified as hyperdiploid B-ALL. Here, we summarize the main cytogenetic and molecular features of hypodiploid B-ALL subtypes, and provide a brief overview of the diagnostic methods, standard-of-care treatments and overall clinical outcome. Finally, we discuss molecular mechanisms that may underlie the origin and leukemogenic impact of hypodiploidy and may open new therapeutic avenues to improve survival rates in these patients.

16 July 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AFAnna Faura
Anna Faura
ÁLÁlvaro Lassaletta
Álvaro Lassaletta
ESElena Sebastián
Elena Sebastián
LMLuis Madero
Luis Madero
JHJorge Huerta
Jorge Huerta
JDJosé Luis Dapena
José Luis Dapena

13 September 2012 in British Journal of Cancer
Verified
Journal Article
Open access
AMA Masià
A Masià
AAA Almazán-Moga
A Almazán-Moga
PVP Velasco
P Velasco
JRJ Reventós
J Reventós
NTN Torán
N Torán
SGSoledad Gallego
Soledad Gallego
Background: Methods: Results: Conclusion:

7 September 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
AAA Almazán-Moga
A Almazán-Moga
PZPatricia Zarzosa
Patricia Zarzosa
CMC Molist
C Molist
PVP Velasco
P Velasco
JPJ Pyczek
J Pyczek
SGSoledad Gallego
Soledad Gallego
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH) pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway in RMS is not well understood. The expression of HH ligands was studied by qPCR, western blot and immunohistochemistry. Functional and animal model studies were carried out with cells transduced with shRNAs against HH ligands or treated with HH-specific inhibitors (Vismodegib and MEDI-5304). Finally, the molecular characterisation of an off-target effect of Vismodegib was also made. The results showed a prominent expression of HH ligands supporting an autocrine ligand-dependent activation of the pathway. A comparison of pharmacologic Smoothened inhibition (Vismodegib) and HH ligand blocking (MEDI-5304) is also provided. Interestingly, a first description of pernicious off-target effect of Vismodegib is also reported. The clarification of the HH pathway activation mechanism in RMS opens a door for targeted therapies against HH ligands as a possible alternative in the future development of better treatment protocols. Moreover, the description of a pernicious off-target effect of Vismodegib, via unfolded protein response activation, may mechanistically explain its previously reported inefficiency in several ligand-dependent cancers.